Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effaclar Duo (+) as Adjuvant Therapy for Acne Vulgaris
NCT05497323Phase 1Unknown
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of Effaclar Duo (+) in acne vulgaris (3 arms). Primary endpoints: Change of acne severity at Day 56, Change of Level Of Seborrhea at Day 56 and 3 more. Status: unknown.
02
Drugs
Effaclar Duo (+)
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT05497323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497323.